Wegovy 7.2mg, what you need to know

Wegovy 7.2mg is the highest approved weekly dose of semaglutide for weight management. It offers additional support for people who have not reached their weight loss goals on the standard 2.4mg maintenance dose.

In this guide, our clinicians explain what Wegovy 7.2mg is, how it compares to other treatments, and how myBMI can support you if you're considering the higher dose.

Key points

● Wegovy 7.2mg is the highest approved dose of semaglutide for weight management, designed for patients who need additional support beyond the 2.4mg dose.

● In the STEP UP trial, patients on 7.2mg achieved an average weight loss of around 21%, with almost 1 in 3 losing 25% or more of their body weight.

● The 7.2mg dose is now available in Ireland through myBMI.

What is Wegovy 7.2mg?

Wegovy 7.2mg is a higher maintenance dose of semaglutide, which is the same active ingredient used across all doses of Wegovy. You might consider increasing your dose to 7.2mg if you’re already on 2.4mg but aren’t seeing the results you want.

How does Wegovy 7.2mg work?

“Semaglutide is a GLP-1 receptor agonist. It works by mimicking a natural gut hormone that helps regulate your appetite, slow digestion, and support blood sugar control.

“At 7.2mg, the effects of the treatment are stronger. This means it can help further reduce your appetite, potentially leading to greater weight loss when combined with a continuation of the healthy lifestyle habits you introduced while on the lower doses of Wegovy.”

Niyah Mansuri, weight loss expert at myBMI

Is Wegovy 7.2mg available in Ireland?

Yes. Wegovy 7.2mg is available in Ireland through myBMI. It’s taken as 3 x 2.4mg injections each week, though a single dose pen is currently being reviewed for approval.

How much weight can you lose on Wegovy 7.2mg?

The STEP UP trial studied approximately 1,400 adults with obesity over 72 weeks. For patients that used the treatment as instructed, and combined it with a healthier diet and more physical activity, the average weight loss was nearly 21% of their starting body weight.

The trial also showed that a significantly higher proportion of patients reached key weight loss milestones at the higher dose, with 93.2% of patients on 7.2mg losing at least 5% of their body weight.

All this said, remember that individual results will vary depending on your starting weight, health conditions, and how closely you follow your diet and exercise plan.

Who is Wegovy 7.2mg for?

Wegovy 7.2mg is designed for people who’ve already been taking Wegovy 2.4mg and either haven't reached their weight loss goals, or want additional support with long-term weight management.

It may be suitable for you if:

• You have been on the 2.4mg dose for at least 4 weeks, and your weight loss has slowed or plateaued.
• You haven't experienced the results you were hoping for at 2.4mg despite following dietary and exercise guidance.
• Your clinician recommends a higher maintenance dose based on your individual health needs.
• You are looking for a higher dose to support long-term weight maintenance after initial weight loss.

When can I switch to Wegovy 7.2mg?

Keep in mind that Wegovy 7.2mg isn’t a starting dose. You must have completed the standard Wegovy titration schedule and been stable on 2.4mg before moving to the higher dose.

Moving to 7.2mg is typically considered once you have been on the 2.4mg dose for at least 4 weeks and your clinician has reviewed how you are responding to treatment.

Switching to 7.2mg should only happen under the guidance of your clinician. Your prescriber will assess whether the higher dose is appropriate based on your progress, how well you're dealing with any side effects, and your overall health.

If you are a current myBMI patient and want to discuss whether 7.2mg could be right for you, speak to one of our experts at your next consultation.

How to take Wegovy 7.2mg

Wegovy 7.2mg is currently taken as 3 x 2.4mg injections a week.

For detailed instructions on administration, including site rotation and needle disposal, see how to inject Wegovy.

Potential Wegovy 7.2mg side effects

The most common side effects of Wegovy 7.2mg are largely the same as at lower doses.

This includes nausea, vomiting, diarrhoea, constipation, and stomach pain. Additional side effects may include headaches, heartburn, fatigue, and hair loss. These are typically mild to moderate and tend to settle as your body adjusts.

In the STEP UP trial, gastrointestinal side effects were reported by 71% of patients on the 7.2mg dose compared with 61% on 2.4mg. Just 3.3% of patients on 7.2mg discontinued treatment due to side effects.

One side effect that is more common at the 7.2mg dose than lower doses is dysaesthesia. This refers to unusual skin sensations such as tingling, burning, numbness, or heightened sensitivity.

In the STEP UP trial, dysaesthesia was reported by around 23% of patients on 7.2mg, compared with approximately 6% on 2.4mg. While uncomfortable, dysaesthesia is not considered dangerous and often resolves on its own or after a dose adjustment.

If you experience any new or worsening side effects after moving to 7.2mg, speak to your clinician, and they can help you navigate your symptoms.

Wegovy 7.2mg vs Mounjaro

At their highest doses, Wegovy and Mounjaro have shown comparable weight loss results in clinical trials. The main differences are in their active ingredients, how they work, and, at present, how you take them.

Both treatments are clinically proven and effective. Mounjaro targets 2 hormone receptors (GIP and GLP-1), while Wegovy targets one (GLP-1). Despite this difference, the amount of weight you can lose at the highest doses of both treatments is very similar.

The right treatment depends on your individual health, how you respond to each medication, and your budget. Your prescriber can help you decide whether Wegovy 7.2mg or Mounjaro is more appropriate for your needs.

How myBMI can help

If you’re already taking Wegovy 2.4mg with myBMI and want to explore whether the 7.2mg dose could support your progress, the process is straightforward.

Your prescriber will review your treatment history, current weight loss progress, and any side effects you’ve experienced. If they determine that the higher dose is clinically appropriate, they’ll update your prescription and arrange your supply.

If you’re new to myBMI, the first step is to complete a clinical consultation. Our clinicians will assess your eligibility, discuss your health goals, and recommend the most suitable treatment plan for you. You will always start on a lower dose and follow the standard titration schedule before any higher dose is considered.

Throughout your treatment, you will have access to:

• Ongoing clinical oversight from qualified healthcare professionals.
• Guidance on nutrition, movement, and lifestyle changes that support your progress.
• Side effect management advice and treatment support.
• Transparent pricing with no hidden fees.

Our goal is to support you with safe, effective, evidence-based care to help you accomplish your goals. You can get started here.

Frequently asked questions about Wegovy 7.2mg

Is Wegovy 7.2mg safe?

Yes, Wegovy 7.2mg has been approved by the European Commission based on extensive Phase 3 clinical trial data. The safety and tolerability profile is consistent with lower doses of semaglutide, with the most common side effects being gastrointestinal.

The main difference is a higher rate of dysaesthesia (unusual skin sensations) at 7.2mg compared with 2.4mg. This side effect is generally not dangerous and can often be managed with clinical guidance. Your prescriber will monitor your progress and adjust your treatment if needed.

How much does Wegovy 7.2mg cost?

Pricing will depend on your current prescription plan with myBMI. For up-to-date pricing, visit our Wegovy prices page or speak to our team during your consultation.

myBMI's pricing includes your consultation, prescription, medication, and ongoing clinical support.

Can I move back from Wegovy 7.2mg to 2.4mg?

Yes. If you experience side effects that are difficult to manage at 7.2mg, or if your clinician recommends a dose adjustment, you can return to 2.4mg. Your prescriber will discuss this with you and make sure any changes to your dose are safe and appropriate.

Some patients may find that 2.4mg is the right long-term maintenance dose for them, while others benefit from the higher dose. Treatment is always tailored to your individual needs and response.

Summary of Wegovy 7.2mg

“Wegovy 7.2mg if worth considering if you aren’t seeing the results you want at 2.4mg, or you want a bit of extra support during maintenance.

“It’s safe, shares similar side effects to lower doses of Wegovy, and offers similar levels of weight loss to Mounjaro 15mg.

“If you have any questions, reach out to one of our experts, and we can help you take your next step with confidence.”

Niyah Mansuri, weight loss expert at myBMI

Sources

• Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. (2025) The Lancet Diabetes & Endocrinology. [Accessed 24 May 2026]
• European Commission approves 7.2 mg once-weekly Wegovy dose for adults with obesity. (2026) BioPharm International. [Accessed 24 May 2026]
• CHMP recommends EU approval of Wegovy 7.2 mg in a single-dose pen. (2026) Novo Nordisk via GlobeNewsWire. [Accessed 24 May 2026]
• CHMP recommends EU approval of Wegovy 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss. (2026) Novo Nordisk via Yahoo Finance. [Accessed 24 May 2026]
• Wegovy side effects. Novo Nordisk (Wegovy.com). [Accessed 24 May 2026]
• Wegovy pen guide and dosing information. Novo Nordisk (Wegovy.com). [Accessed 24 May 2026]
• Higher-dose semaglutide approved under new FDA accelerated review process. (2026) The American Journal of Managed Care. [Accessed 24 May 2026]
• Lilly's SURMOUNT-1 results published in the New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight. (2022) Eli Lilly and Company. [Accessed 24 May 2026]